MedTrace Logo

SR-BI and Antiviral Treatment Response in HCV

NCT02714712 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 309

Last updated 2017-07-14

No results posted yet for this study

Summary

The scavenger receptor type B class I (SR-BI) is a receptor for high-density lipoproteins (HDL) and one of entry factors for hepatitis C virus (HCV). The investigators aimed to examine the association of single nucleotide polymorphisms (SNPs) of the SCARB1 gene, which encodes SR-BI, with virologic responses to pegylated interferon-based treatment in Asian chronic hepatitis C (CHC) patients.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Peginterferon alfa-2a

Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks

Sponsors & Collaborators

  • Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-07-31
Completion
2016-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02714712 on ClinicalTrials.gov